For research use only. Not for therapeutic Use.
LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection[1].
LFHP-1c (1, 2, or 5 μmol/L; 9 h) treatment, and followed by hypoxic treatment, increases NRF2 protein expression and facilitates nuclear translocation of NRF2 in primary rat brain microvascular endothelial cells (rBMECs)[1].
LFHP-1c (5 mg/kg; iv; 2 doses) prevents BBB disruption after transient middle cerebral artery occlusion (tMCAO) in rats[1].
LFHP-1c (3 mg/kg, 1 mL/kg; iv; 8 doses) ameliorates brain ischemic injury in tMCAO model of M. fascicularis through PGAM5–NRF2 axis[1].
| Catalog Number | I041198 |
| CAS Number | 2102347-47-5 |
| Synonyms | 1-[2-[8-[[2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoyl]amino]octylcarbamoyl]phenyl]pentyl acetate |
| Molecular Formula | C55H64N6O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C55H64N6O4/c1-6-8-28-50(65-39(4)62)44-23-14-16-25-46(44)55(64)57-34-20-12-10-9-11-19-33-56-54(63)45-24-15-13-22-43(45)41-31-29-40(30-32-41)37-61-49-36-42(35-38(3)52(49)59-51(61)21-7-2)53-58-47-26-17-18-27-48(47)60(53)5/h13-18,22-27,29-32,35-36,50H,6-12,19-21,28,33-34,37H2,1-5H3,(H,56,63)(H,57,64) |
| InChIKey | OITTXMIOSJEXLY-UHFFFAOYSA-N |
| SMILES | CCCCC(C1=CC=CC=C1C(=O)NCCCCCCCCNC(=O)C2=CC=CC=C2C3=CC=C(C=C3)CN4C5=C(C(=CC(=C5)C6=NC7=CC=CC=C7N6C)C)N=C4CCC)OC(=O)C |
| Reference | [1]. Gao C, et al. A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke. Acta Pharm Sin B. 2021 Jul;11(7):1867-1884. |
